Pfizer-Wyeth Merger Set To Transform China’s Pharmaceutical Industry
This article was originally published in PharmAsia News
Executive Summary
After Pfizer's announced intention to acquire Wyeth, informed sources reveal that both firms' business and personnel changes in China will start this Q4. Pfizer said the move will strengthen its business and brand name as well as cut expenses. However, nothing is mentioned about the fate of Wyeth's nutritional products - especially milk powder - that make up its main income in the country. Analysts think the merger will not directly impact the local industry since 97 percent of domestic products comprise generic drugs different from Pfizer's product lines. In the short term, these firms can look forward to cloning the giant's about-to-expire patent drugs. Even so, a growing Pfizer will force the local pharmaceutical industry to upgrade and transform itself in the long run. (Click here for more - Chinese language)